U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. International Activities
  4. International Engagements to Respond to Covid-19 Pandemic
  1. International Activities

International Engagements to Respond to Covid-19 Pandemic

CBER has substantially increased its international efforts in addressing the COVID-19 pandemic.  This includes regulatory and research collaborations regarding COVID-19 vaccine and convalescent plasma products.  By providing scientific and regulatory strategies to facilitate the development, authorization, and availability of COVID-19 vaccines and treatments, CBER contributes to the reduction and spread of COVID-19.

International map with figures

During the pandemic, international regulatory agencies facing travel restrictions have shared inspection information. As with other FDA components, CBER has provided and received a wealth of inspectional information to and from its confidential partners. The CBER International Affairs Team has facilitated inspection information exchange through daily coordination and communication with international partners.

CBER participates in ongoing international pharmacovigilance efforts, including those organized by the International Coalition of Medicines Regulatory Authorities (ICMRA). CBER’s collaborations with ICMRA facilitate information exchange during the ongoing COVID-19 pandemic among global health regulatory authorities. Also, CBER facilitates important exchanges of information and views on the following ICMRA Working Groups: COVID-19 Working Group, Pregnancy and Lactation in COVID-19, COVID-19 Pharmacovigilance Network, Observational Studies and Real World Evidence.

person in protective gear injecting a small globe

CBER continues to engage structured scientific and policy discussions under confidentiality commitments with foreign regulatory counterparts.  For example, CBER participates in regulatory “clusters” (working groups) with international partners such as the European Medicines Agency (EMA) and the Health Products and Food Branch of Health Canada.  Clusters are made up of regulatory experts who meet routinely to discuss regulatory and scientific issues of mutual interest.  CBER is a principal participant in the Clusters for Blood Products, Advanced Therapy Medicinal Products, and Vaccines, and additionally participates as appropriate in the Agency Oncology, Pediatric, Pharmacovigilance, Biosimilar and Pharmacogenomic Clusters. 

CBER participates in discussions in various cluster meetings to ensure a deeper understanding of agencies regulatory approaches and undertake mutual information sharing on COVID-19 products safety and efficacy, and inspection activities. CBER technical experts contribute to international COVID-19 vaccine safety efforts by participating in the FDA/EMA pharmacovigilance cluster.   

In addition, the CBER International Affairs Team collaborates with CBER scientific experts to identify strategic technical areas across CBER for which collaboration with foreign counterparts will add value to CBER’s mission.

The information sharing mutually complements the work CBER’s COVID-19 product authorization activities.  CBER utilizes the FDA Confidentiality Commitments tools for regulatory and research exchanges.  All agency confidentiality commitments are listed on the FDA website for reference.

globe of flags
Back to Top